Developer docs
API playgroundTry for free, no card

Search company profiles

Advent Life Sciences

Full company profile

uuid0003lzx

Namestring
Advent Life Sciences
Legal namestring
Advent Life Sciences LLP
Websiteurl
adventls.com
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Advent Life Sciences LLP is a London-based venture capital firm, structured as an LLP, that has been investing in life sciences companies since 2006 across the UK, Europe, and the United States. The firm focuses on early and mid-stage businesses with first-in-class or best-in-class approaches spanning new drug discovery across all modalities, med tech, enabling technologies, and vaccines. It typically invests at Seed through Series C stages and frequently takes lead or co-lead positions, working in close operational partnership with portfolio management teams.

The firm's single core service is venture investment in life sciences; its "product" is capital plus intellectual and network support rather than a technology platform. Reported portfolio activity since 2020 includes lead investments in Amphista Therapeutics ($7.5M Series A, targeted protein degradation) and PIC Therapeutics ($5M Seed, eIF4E modulators), and participation in rounds for Beacon Therapeutics ($75M+ Series C, ocular gene therapy), Cyted Health ($44M Series B, GI diagnostics), Glycomine ($115M Series C, PMM2-CDG), Relief Cardiovascular ($12M Series A), Epitopea ($31M pre-Series A), and Pheno Therapeutics (£5M Series A, MS remyelination). Portfolio milestones include the October 2024 FDA approval of Iterum Therapeutics' ORLYNVAH (the first oral penem approved in the US) and the October 2025 US approval of Bayer's Lynkuet (elinzanetant), originally developed by Advent-backed KaNDy Therapeutics.

Advent generates revenue through traditional VC mechanics: management fees on committed fund capital and realized investment gains from portfolio exits via acquisitions, IPOs (e.g., Aura Biosciences, NASDAQ: AURA), or strategic transactions. The firm claims that since 2006, Advent-backed companies have brought 15 innovative medicines and products to approval, with the mid- and late-stage clinical pipeline expected to drive additional exits. The firm is privately held, has 11-50 employees, and its financial figures are not publicly disclosed.

Short descriptiontext

Advent Life Sciences is a London-based venture capital firm (LLP) founded in 2006 that invests Seed through Series C in early and mid-stage life sciences companies across the UK, Europe, and the USA, backing first-in-class or best-in-class drug discovery, med tech, enabling technologies, and vaccines.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
life sciences venture capital, biotech venture investing, drug discovery funding, med tech investments, healthcare venture capital
Industry1 code
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking
NAICS code2 codes
  • Other Scientific and Technical Consulting Services54169
  • Scientific Research and Development Services5417
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital (Life Sciences)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Investment Returns
TypeLicensing Royalties
Description

Advent Life Sciences generates returns through equity investments in portfolio companies, realizing gains through exits via acquisitions, IPOs, or other strategic transactions. Since 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval.

adventls.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Personnel, Operations, Technology or R&D
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Advent Life Sciences is a trans-Atlantic venture capital firm that founds and invests in early and mid-stage life sciences companies with first-in-class or best-in-class approaches to unmet medical needs. The firm provides venture capital, strategic guidance, and operational support across new drug discovery (all modalities), med tech, enabling technologies, and vaccines. It takes a hands-on, partnership-oriented approach working closely with portfolio management teams to advance breakthrough science toward approved medicines and medical products.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • 15 innovative medicines and products brought to approval since 2006
Product overview1 text field

Advent Life Sciences is a venture capital firm offering a single unified investment service rather than a product portfolio. The firm focuses on identifying, funding, and supporting early and mid-stage life sciences companies developing innovative medicines and medical technologies. Their investment approach emphasizes breakthrough science with a first-in-class or best-in-class strategy across drug discovery, med tech, enabling technologies, and vaccines. The firm takes a hands-on, partnership-oriented approach with portfolio companies, providing intellectual capital and operational support to turn scientific innovation into approved medicines or medical products.

Product and service1 record
1Advent Life Sciences Venture Investment Services
CategoryVenture Capital Investment
Description

Trans-Atlantic venture capital investment and hands-on operational support for early and mid-stage life sciences companies pursuing first-in-class or best-in-class approaches across drug discovery, med tech, enabling technologies, and vaccines. Targeted at founders and management teams of innovative biotechnology and medical technology companies.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierPortfolio CompanyTypeStrategic or Co-development PartnerAnnounced on2019-12-10
Description

Bioncotech Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, entered a Phase II clinical trial collaboration with MSD (Merck & Co.) for BO-112 combined with KEYTRUDA.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Venture arm of Merck KGaA investing across life sciences, including early-stage biotech and enabling technologies. Overlapping mandate with Advent's enabling-technologies and therapeutics scope.

TypeDirect peer
Description

London/SF/New York venture firm with a dedicated life sciences practice investing in biotech across modalities from early to mid stages. Comparable transatlantic mandate and stage focus.

3EQT Life Sciences
TypeDirect peer
Description

European life sciences VC (formerly LSP) investing from seed to growth across biotech and medtech. Direct peer — has co-invested with Advent on Cyted Health Series B and shares the European-anchored transatlantic thesis.

TypeDirect peer
Description

Paris- and London-headquartered VC firm exclusively dedicated to life sciences investing across early and mid-stage companies in drug discovery and medtech. Closest direct analogue to Advent's European-anchored transatlantic life sciences strategy.

TypeDirect peer
Description

Leading European life sciences VC investing in early to late-stage biotech and medtech. Comparable in transatlantic presence, therapeutic diversification and a track record of approvals/exits across portfolio companies.

TypeBroad incumbent
Description

Fidelity-affiliated global venture firm with a deep life sciences practice across biotech, medtech and healthcare. Larger incumbent that overlaps Advent's mandate at the upper end of stage range.

TypeDirect peer
Description

UK-based transatlantic life sciences and healthcare VC that invests across all clinical stages and modalities. Highly comparable firm by mandate and geographic focus.

TypeDirect peer
Description

Copenhagen-headquartered life sciences investor running seed, venture and growth strategies. Comparable focus on first-in-class biotech and a long-dated, multi-stage European life sciences platform.

TypeDirect peer
Description

UK-based technology and life sciences VC investing at early stages across UK and Europe. Comparable in geography, size and stage focus though broader sector mandate than Advent.

TypeDirect peer
Description

Boston/London-based specialist healthcare VC investing across biotech, medtech and growth-stage healthcare. Comparable therapeutic breadth and dual-continent approach to Advent.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment70 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Advent Life Sciences

Venture Capital (Life Sciences)adventls.com

Advent Life Sciences is a London-based venture capital firm (LLP) founded in 2006 that invests Seed through Series C in early and mid-stage life sciences companies across the UK, Europe, and the USA, backing first-in-class or best-in-class drug discovery, med tech, enabling technologies, and vaccines.

What Advent Life Sciences does

Advent Life Sciences LLP is a London-based venture capital firm, structured as an LLP, that has been investing in life sciences companies since 2006 across the UK, Europe, and the United States. The firm focuses on early and mid-stage businesses with first-in-class or best-in-class approaches spanning new drug discovery across all modalities, med tech, enabling technologies, and vaccines. It typically invests at Seed through Series C stages and frequently takes lead or co-lead positions, working in close operational partnership with portfolio management teams.

The firm's single core service is venture investment in life sciences; its "product" is capital plus intellectual and network support rather than a technology platform. Reported portfolio activity since 2020 includes lead investments in Amphista Therapeutics ($7.5M Series A, targeted protein degradation) and PIC Therapeutics ($5M Seed, eIF4E modulators), and participation in rounds for Beacon Therapeutics ($75M+ Series C, ocular gene therapy), Cyted Health ($44M Series B, GI diagnostics), Glycomine ($115M Series C, PMM2-CDG), Relief Cardiovascular ($12M Series A), Epitopea ($31M pre-Series A), and Pheno Therapeutics (£5M Series A, MS remyelination). Portfolio milestones include the October 2024 FDA approval of Iterum Therapeutics' ORLYNVAH (the first oral penem approved in the US) and the October 2025 US approval of Bayer's Lynkuet (elinzanetant), originally developed by Advent-backed KaNDy Therapeutics.

Advent generates revenue through traditional VC mechanics: management fees on committed fund capital and realized investment gains from portfolio exits via acquisitions, IPOs (e.g., Aura Biosciences, NASDAQ: AURA), or strategic transactions. The firm claims that since 2006, Advent-backed companies have brought 15 innovative medicines and products to approval, with the mid- and late-stage clinical pipeline expected to drive additional exits. The firm is privately held, has 11-50 employees, and its financial figures are not publicly disclosed.

Advent Life Sciences firmographics

Firmographics
Name
Advent Life Sciences
Legal name
Advent Life Sciences LLP
Website
https://adventls.com
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
11–50 employees
Short description
Advent Life Sciences is a London-based venture capital firm (LLP) founded in 2006 that invests Seed through Series C in early and mid-stage life sciences companies across the UK, Europe, and the USA, backing first-in-class or best-in-class drug discovery, med tech, enabling technologies, and vaccines.
Ownership category
akta.pro rank

Advent Life Sciences industry classification

Industry
Product category
Venture Capital (Life Sciences)
NAICS
Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYBPAGAKAL
Health & Medical Research Grantmaking Foundations
Business & Public Services/Nonprofit, NGO & Social Services/Philanthropy, Foundations & Grantmaking

Keywords

  • Life sciences venture capital
  • Biotech venture investing
  • Drug discovery funding
  • Med tech investments
  • Healthcare venture capital

Where Advent Life Sciences is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Advent Life Sciences business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D

Revenue model

  1. Investment Returns: Advent Life Sciences generates returns through equity investments in portfolio companies, realizing gains through exits via acquisitions, IPOs, or other strategic transactions. Since 2006, Advent-backed companies have brought fifteen innovative medicines and products to approval.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Advent Life Sciences product offering

Product offering

Core offering

Advent Life Sciences is a trans-Atlantic venture capital firm that founds and invests in early and mid-stage life sciences companies with first-in-class or best-in-class approaches to unmet medical needs. The firm provides venture capital, strategic guidance, and operational support across new drug discovery (all modalities), med tech, enabling technologies, and vaccines. It takes a hands-on, partnership-oriented approach working closely with portfolio management teams to advance breakthrough science toward approved medicines and medical products.

Product overview

Advent Life Sciences is a venture capital firm offering a single unified investment service rather than a product portfolio. The firm focuses on identifying, funding, and supporting early and mid-stage life sciences companies developing innovative medicines and medical technologies. Their investment approach emphasizes breakthrough science with a first-in-class or best-in-class strategy across drug discovery, med tech, enabling technologies, and vaccines. The firm takes a hands-on, partnership-oriented approach with portfolio companies, providing intellectual capital and operational support to turn scientific innovation into approved medicines or medical products.

Differentiator

Problem solved

Functional benefit

Products and services

  • Advent Life Sciences Venture Investment Services Trans-Atlantic venture capital investment and hands-on operational support for early and mid-stage life sciences companies pursuing first-in-class or best-in-class approaches across drug discovery, med tech, enabling technologies, and vaccines. Targeted at founders and management teams of innovative biotechnology and medical technology companies.

Quantifiable outcome

  • 15 innovative medicines and products brought to approval since 2006

Companies that use Advent Life Sciences

Customer profile

Segments1 record

Ideal customer profiles1 record

Advent Life Sciences technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Advent Life Sciences partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Bioncotech Therapeuticsportfolio companyStrategic or Co-development Partner · 10 December 2019Bioncotech Therapeutics, a clinical-stage biopharmaceutical company developing RNA-based therapies against cancer, entered a Phase II clinical trial collaboration with MSD (Merck & Co.) for BO-112 combined with KEYTRUDA.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Advent Life Sciences competitors and assessment

Company assessment

Direct peers

  • M Ventures: Venture arm of Merck KGaA investing across life sciences, including early-stage biotech and enabling technologies. Overlapping mandate with Advent's enabling-technologies and therapeutics scope.
  • Index Ventures (Life Sciences): London/SF/New York venture firm with a dedicated life sciences practice investing in biotech across modalities from early to mid stages. Comparable transatlantic mandate and stage focus.
  • EQT Life Sciences: European life sciences VC (formerly LSP) investing from seed to growth across biotech and medtech. Direct peer — has co-invested with Advent on Cyted Health Series B and shares the European-anchored transatlantic thesis.
  • Sofinnova Partners: Paris- and London-headquartered VC firm exclusively dedicated to life sciences investing across early and mid-stage companies in drug discovery and medtech. Closest direct analogue to Advent's European-anchored transatlantic life sciences strategy.
  • Forbion: Leading European life sciences VC investing in early to late-stage biotech and medtech. Comparable in transatlantic presence, therapeutic diversification and a track record of approvals/exits across portfolio companies.
  • Abingworth: UK-based transatlantic life sciences and healthcare VC that invests across all clinical stages and modalities. Highly comparable firm by mandate and geographic focus.
  • Novo Holdings (Novo Seeds / Novo Ventures): Copenhagen-headquartered life sciences investor running seed, venture and growth strategies. Comparable focus on first-in-class biotech and a long-dated, multi-stage European life sciences platform.
  • AlbionVC: UK-based technology and life sciences VC investing at early stages across UK and Europe. Comparable in geography, size and stage focus though broader sector mandate than Advent.
  • SV Health Investors: Boston/London-based specialist healthcare VC investing across biotech, medtech and growth-stage healthcare. Comparable therapeutic breadth and dual-continent approach to Advent.

Broad incumbents

  • F-Prime Capital: Fidelity-affiliated global venture firm with a deep life sciences practice across biotech, medtech and healthcare. Larger incumbent that overlaps Advent's mandate at the upper end of stage range.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights6 records

Customer concentration

Advent Life Sciences social profiles

Digital presence

Advent Life Sciences financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Advent Life Sciences leadership team

Management profile

Number of profiles

Profiles4 records

Advent Life Sciences funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Advent Life Sciences M&A and investment

M&A and investment

M&A

Investments70 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Advent Life Sciences

What does Advent Life Sciences do?

Advent Life Sciences is a trans-Atlantic venture capital firm that founds and invests in early and mid-stage life sciences companies with first-in-class or best-in-class approaches to unmet medical needs. The firm provides venture capital, strategic guidance, and operational support across new drug discovery (all modalities), med tech, enabling technologies, and vaccines. It takes a hands-on, partnership-oriented approach working closely with portfolio management teams to advance breakthrough science toward approved medicines and medical products.

Is Advent Life Sciences a public or private company?

Advent Life Sciences is a private company. It is classified as management employee owned and is currently operating.

When was Advent Life Sciences founded?

Advent Life Sciences was founded in 2006. It employs 11 to 50 people.

Where is Advent Life Sciences based?

Advent Life Sciences is headquartered in London, United Kingdom, in the Europe region.

How does Advent Life Sciences make money?

One revenue line is on record: investment Returns.

Who are Advent Life Sciences's main competitors?

Direct peers on record are M Ventures, Index Ventures (Life Sciences), EQT Life Sciences, Sofinnova Partners, Forbion, Abingworth, Novo Holdings (Novo Seeds / Novo Ventures), AlbionVC and SV Health Investors. F-Prime Capital is listed as a broad incumbent.

Does Advent Life Sciences have an API?

No public API is recorded for Advent Life Sciences.

What industry is Advent Life Sciences in?

Advent Life Sciences's product category is Venture Capital (Life Sciences). Its primary akta.pro industry code is BPAGAKAL, Health & Medical Research Grantmaking Foundations. Its NAICS code is 54169 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketScreenerT-Therapeutics Limited announced that it has received $133 million in funding from a group of investorsT-Therapeutics Limited announced a $133 million funding round co-led by Advent Life Sciences and British Business Bank on November 5, 2026. The round included participation from Johnson & Johnson, Eli Lilly, Merck, and others, with convertible preferred shares issued.InvestorsinhealthcareUK: British Business Bank to commit up to £135m to two new Advent Life Sciences fundsThe British Business Bank committed £60m to Advent Life Sciences Fund IV and £75m to Advent Life Sciences Growth Fund, totaling £135m. The investments aim to support UK life sciences companies from early-stage development through commercialisation. The bank has partnered with Advent since 2019.Pulse 2.0Advent Life Sciences Appoints Gail Jermyn Investor Relations PartnerAdvent Life Sciences appointed Gail Jermyn as Investor Relations Partner to lead investor relations and fundraising. She brings over two decades of experience, including roles at Weight Partners Capital and BC Partners. The appointment supports Advent's ongoing investments in drug discovery and medtech.European BiotechnologyMacrocycles: big is the new beautifulMacrocycles, large ring-shaped molecules, are emerging as a drug class for difficult targets, with European startups Orbis Medicines and Curve Therapeutics leading. Curve raised £40.5 million in Series A funding, and Novartis licensed Unnatural Products' macrocyclic programs for cardiovascular disease, with fees up to $1.7 billion.GlycomineGlycomine Announces $115 Million Series C Financing to Advance Lead Drug Candidate, GLM101, into a Phase 2b Clinical Trial for PMM2-CDGGlycomine announced a $115 million Series C financing to advance its lead drug GLM101 into a Phase 2b clinical trial for PMM2-CDG. The funding, led by CTI Life Sciences Fund and Advent Life Sciences, will support a randomized, placebo-controlled trial later this year. GLM101 is the first disease-modifying therapy in development for this rare disorder.ArgamedtechArgá Medtech SA closes Oversubscribed Series BArgá Medtech SA closed an oversubscribed €54 million Series B funding round led by Advent Life Sciences, Earlybird Health, and Gilde Healthcare. The capital will be used to advance US and EU clinical studies for its Coherent Sine-Burst Electroporation pulsed field ablation system and expand its San Diego operations.PR NewswireWondr Medical raise £12 million in seed round led by Advent Life Sciences and Sonder Capital to accelerate global collaboration across the medical communityLondon-based digital health start-up Wondr Medical raised £12 million in a seed round co-led by Advent Life Sciences and Sonder Capital, with participation from existing shareholders. Founded in 2020, the HIPAA-compliant platform recently reached 200,000 members and plans to launch the "Wondr Medical Rooms" mobile app. The company also appointed David Ellam as CFO, Leyla Pope as COO, Max Peters as CTO and Stephen Taylor as CRO.PR NewswireWondr Medical raise £12 million in seed round led by Advent Life Sciences and Sonder Capital to accelerate global collaboration across the medical communityDigital health startup Wondr Medical has raised £12 million in a seed funding round co-led by Advent Life Sciences and Sonder Capital. The company, which recently onboarded its 200,000th member, intends to use the funds to expand its global medical collaboration platform and launch the 'Wondr Medical Rooms' mobile app. This investment supports the company's mission to connect healthcare professionals for better clinical information sharing.PR NewswireAdvent Life Sciences Announces Growth of Investment Team with Three Senior AppointmentsAdvent Life Sciences announced the appointment of three senior investment specialists—Dominic Schmidt, Satish Jindal, and Katrine Bosley—to its leadership team. This expansion brings the firm's total investment professionals to 18, aiming to strengthen its capabilities in backing innovative life science companies across the UK, Europe, and the US.IFTTTUK VC Advent Life Sciences raises £153M to support companies that translate early-stage research into impactful medicinesAdvent Life Sciences closed two new funds with $215 million in commitments, including Fund III and the Advent-Harrington Impact Fund. The funds target early- and mid-stage life sciences companies, with the impact fund partnering with Harrington Discovery Institute. The firm has supported 14 approved products and founded over 20 biotech companies in 15 years.